Tuesday, January 17, 2023 2:28:19 PM
exwannabe,
In order for PFS to fail it must be proven that true PFS failed. There is an appeals process that allows proof to be given that true PFS did not fail and proof of treatment induced pseudoprogression can be presented. The fact that PFS had to be adjudicated led to them changing the endpoints entirely as there still is no perfect way to separate true progression from pseudoprogression but the fact that treatment arm patients are living longer in spite of apparent progression confirms the problem.
The issue with endpoint changes on the clinical trials site, unlike Europe where the changes are made by others than the sponsor, is the rational for doing so must be made public first or there could be legal ramifications. This led to the May 10th attack which now is being used to take down the crooks who thought they could get away with what they were doing. FDA will take no issue with what had to happen as the company was blinded and protected by firewall the entire time that changes were made and they had their own blinded data to make determinations about potential PFS problems because of pseudoprogression. They didn’t need others to tell them. Best wishes.
In order for PFS to fail it must be proven that true PFS failed. There is an appeals process that allows proof to be given that true PFS did not fail and proof of treatment induced pseudoprogression can be presented. The fact that PFS had to be adjudicated led to them changing the endpoints entirely as there still is no perfect way to separate true progression from pseudoprogression but the fact that treatment arm patients are living longer in spite of apparent progression confirms the problem.
The issue with endpoint changes on the clinical trials site, unlike Europe where the changes are made by others than the sponsor, is the rational for doing so must be made public first or there could be legal ramifications. This led to the May 10th attack which now is being used to take down the crooks who thought they could get away with what they were doing. FDA will take no issue with what had to happen as the company was blinded and protected by firewall the entire time that changes were made and they had their own blinded data to make determinations about potential PFS problems because of pseudoprogression. They didn’t need others to tell them. Best wishes.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
